Hemispherx extends agreement with Armada Health Care
The agreement now extends through Aug. 14, 2017.
“This extended agreement with Armada is gratifying,” Wayne Springate, senior vice president of operations for Hemispherx, said. “As leaders in the specialty pharmaceutical field, Armada is the ideal partner for the marketing and distribution of Alferon N Injection. Now with our upgrade work complete to include a high volume, state-of- the-art bioreactor for the manufacture of Alferon N Injection, we hope to be able to supply greater volumes of product to the market than in the past.”
Under the agreement, Hemispherx will manufacture and supply Alferon N Injection to physicians and patients through Armada's national network of specialty pharmacies. Armada has agreed to provide ongoing sales and marketing to support the product's relaunch.
"We have closely followed Hemispherx progress in its major upgrade of the Alferon manufacturing facility, and we are pleased that this is now complete and we can continue to work on preparing for the re-launch of Alferon N Injection,” Ryan Oligino, executive vice president of manufacturer relations for Armada Health Care, said. “As the only natural interferon approved in the U.S., we think Alferon N Injection has great potential in our market.”